Treatment of Pediatric Patients w/High Risk Leukemia

A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum A Groupwide Phase III Study

February 21, 2018

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica; Francois, Laetitia Claire; Spinelli, Jennifer; Leffin, Melissa

  • IRB No: AALL1131

    Protocol Abbrev: AALL1131

    Principal Investigator: Vincent F. Giusti, MD

    Sub Investigators: AguilarBonilla, Ana MD; Eslin, Don MD; Martin, Rebecca, ARNP; Pope, Michele ARNP; Smith, Amy MD; Story, Allison ARNP; Sullivan Darden, Kelly ARNP; Sutphin, Robert MD; Wieber, Laura ARNP; Levy, Alejandro MD

    Phase: Drug: Phase III

    Age Group: Pediatric

    Secondary Protocol No: AALL1131

    Treatment: Drug: Chemotherapy (multiple) Radiation: radiation therapy Drug: Steroids

    Applicable Disease Sites: Leukemia

    Therapies Involved: Chemotherapy ID: NCT01406756

  • Objective

    A trial is studying how combination chemotherapy works in treating young patients with acute lymphoblastic leukemia.

  • Key Eligibility

    Ages Eligible for Study: 1 Year to 30 Years; Genders Eligible for Study: Both; Accepts Healthy Volunteers: No